Trinity Life Sciences has introduced a proprietary AI algorithm that accurately forecasted commercial outcomes for over 90% of U.S. drug launches since 2014, significantly outperforming Wall Street analysts, who averaged less than 60% accuracy. The breakthrough is detailed in Trinity’s latest white paper, Predicting Winners: AI-Powered Portfolio Management, which highlights how AI can transform strategic decision-making in the life sciences sector.
The model draws from Trinity’s proprietary Drug Index, analyzing more than 250 launches using over 20 variables, including indication specifics and market dynamics. CEO Leslie Orne stated the algorithm enables “smarter, more informed commercialization decisions,” helping companies optimize R&D investments and identify both high-potential therapies and likely underperformers.
